Biotechnology
Filter News
Found 46,681 articles
-
Tune Therapeutics Unveils Breakthrough Data Showing Stable and Durable Epigenetic Regulation in Non-Human Primates
5/22/2023
At the 26th Annual Meeting of the American Society of Gene & Cell Therapy, leading epigenetic editing company Tune Therapeutics showcased the power and potential of its TEMPO TM genetic tuning platform, by presenting data showing the stable repression of the PCSK9 gene and the effective reduction of LDL-cholesterol levels in non-human primates.
-
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
5/22/2023
AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration, and/or diabetic macular edema.
-
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
5/22/2023
Pieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled Jagged-1 targeting program, PRS-400, at the annual American Thoracic Society (ATS) International Conference being held in Washington, D.C. May 19-24, 2023.
-
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting
5/22/2023
NexImmune, Inc. (Nasdaq: NEXI) today announced that it will be presenting a poster at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held in Boston from June 20-23, 2023.
-
Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102
5/21/2023
Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application of LAE102 antibody to initiate clinical development.
-
In a 12-2 vote with two abstentions, the advisers said the benefits did not outweigh the risks.
-
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
5/20/2023
Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device.
-
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
5/20/2023
Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction.
-
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/20/2023
Senti Biosciences, Inc. announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy annual meeting in Los Angeles, CA.
-
BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share
5/19/2023
BriaCell Therapeutics Corp. is pleased to announce that the Company has completed the previously-announced strategic investment by Prevail Partners, LLC in the Company, in accordance with a stock purchase agreement entered into between the Company and Prevail Partners on May 12, 2023.
-
Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
5/19/2023
Calithera Biosciences, Inc. announced that it intends to hold a special meeting of stockholders on or about June 29, 2023, for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution.
-
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
5/19/2023
Genmab A/S announced that the U.S. Food and Drug Administration has approved EPKINLY™ as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B‑cell lymphoma, after two or more lines of systemic therapy.
-
Cytek Biosciences Announces $50 Million Stock Repurchase Program
5/19/2023
Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law.
-
Eascra Biotech Research Blasts Off with Ax-2 Launch
5/19/2023
Research from Eascra Biotech will be onboard Axiom Mission 2, a private crew mission to the International Space Station set to launch Sunday May 21 from Kennedy Space Station.
-
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
5/19/2023
Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and Drug Administration (FDA) has approved VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).
-
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
5/19/2023
Celularity Inc. (Nasdaq: CELU) (“Celularity”) announced results from an exploratory analysis of Phase 1 data evaluating alterations in gene and protein signatures associated with reduced inflammation and fistula formation resulting from therapy with mesenchymal‐like adherent stromal cells (MLASCs) in adult patients with Crohn’s disease (CD).
-
AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE
5/19/2023
Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.
-
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
5/19/2023
Exicure, Inc., announced it received a notice of non-compliance from Nasdaq Stock Market LLC on May 17, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.
-
Daxor Corporation Announces Proposed Underwritten Public Offering - May 19, 2023
5/19/2023
DAXOR CORPORATION, the global leader in blood volume measurement technology, announces that it has commenced an underwritten public offering of shares of its common stock.
-
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/19/2023
KaliVir Immunotherapeutics, Inc. announced the presentation of new data on its lead pre-clinical candidate VET3-TGI at the American Society of Gene & Cell Therapy 26th Annual Meeting.